PHAR (Pharming Group N.V.) מכפיל P/E עתידי

Pharming Group N.V. relies on a steady cash flow from orphan drug sales to fund new research. The company's forward P/E, which informs this chart via GURU.Markets data, currently stands at 35.60. The business maintains monopoly control over protein production within a narrow niche, while a team of leading biologists is driven by the opportunity to save patients' lives.

Investors use this indicator to identify fundamental valuation supports for an asset. The metric is calculated as the ratio of the current share price to the projected earnings for the upcoming period. The forward P/E history of Pharming Group N.V. (PHAR) visualizes the dynamics of market expectations and the impact of the cost of capital on the business valuation. A compression of the multiple reflects the risks of losing market share. For Pharming Group N.V. (PHAR), this is critical due to pressure from genetic engineering behemoths in the orphan disease niche.